Serum Cytokine of IL-10 and IL-12 in Chronic Liver Disease: The Immune and Inflammatory Response

El-Emshaty, Hoda; Nasif, Wesam A.; Mohamed, Ibrahim E.

doi:10.1155/2015/707254

Cited by 42 publications

(38 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar to previous work, we show elevated IL‐10, an anti‐inflammatory cytokine in our HBV‐infected and HDV‐infected cohorts (Fig. ) . Rise in IL‐10 along with corresponding decline in type 1/regulatory type, type 2/regulatory type, and type 3/type 2 ratios indicates heightened regulatory immunity with disease progression (Table ) and reinforces a possible role of IL‐10 in infection chronicity.…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

The balance of type 1 and type 2 immune responses in the contexts of hepatitis B infection and hepatitis D infection

Townsend

Zhang

Ali

et al. 2019

J of Gastro and Hepatol

View full text Add to dashboard Cite

Background and Aim Hepatitis delta virus (HDV) infection is the most rapidly progressive chronic viral hepatitis. Little is understood about the immune responses to HDV. This study aims to characterize the systemic immune environments of hepatitis B virus (HBV) and HDV patients at various disease stages. Methods A total of 129 subjects were evaluated: 53 HBV, 43 HDV, and 33 healthy controls. HBV and HDV subjects were categorized by aspartate aminotransferase to platelet ratio index (APRI) into mild (APRI < 0.5), moderate, and severe (APRI > 1.0). Serum cytokines and immune markers were assessed at a single treatment‐naïve time‐point. Results Type 1 cytokines are elevated in both HBV and HDV. Both groups show higher tumor necrosis factor‐α (TNF‐α), interleukin (IL)‐12p40, and C–X–C motif chemokine ligand 9 when compared with controls (all P < 0.05). However, only HBV group displayed elevated γ‐interferon compared with controls. Type 2 cytokines are elevated in HBV. HBV group shows higher IL‐4, IL‐13, and C–C motif chemokine ligand (CCL) 26 compared with healthy controls and HDV. Chemokines CCL2 and CCL13 are lower in HDV. When assessing ratios, HDV displays higher γ‐interferon/IL‐4, TNF‐α/IL‐4, and TNF‐α/IL‐13 ratios than HBV and controls. Conclusion Hepatitis B virus and HDV subjects show similarly elevated type 1 cytokines. HDV subjects display relatively lower type 2 cytokines. These differences in the systemic immune environments, particularly the predominance of type 1 responses, may contribute to the comparatively rapid progression of HDV disease. Characterization of the imbalance in type 1 and type 2 immunity unique HDV has the potential to provide immunological insights for designing therapeutic targets in HDV‐associated disease progression.

show abstract

Section: Discussionsupporting

confidence: 90%

“…3). 6,16,42,43 Rise in IL-10 along with corresponding decline in type 1/regulatory type, type 2/regulatory type, and type 3/type 2 ratios indicates heightened regulatory immunity with disease progression (Table 3) and reinforces a possible role of IL-10 in infection chronicity.…”

Section: Innate Immunity In Hepatitis B and Dmentioning

confidence: 84%

The balance of type 1 and type 2 immune responses in the contexts of hepatitis B infection and hepatitis D infection

Townsend

Zhang

Ali

et al. 2019

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…The results of the present work showed that both HCV-AI and HCV-NAI patients had significantly higher levels of IL-10 compared to healthy controls which agrees with both Piazzolla et al [50] who showed that serum IL-10 levels were higher among chronic HCV patients compared to controls, and El-Emshaty et al [22] reported the same on Egyptian subjects. Mikadze and Vashakidze [54] reported a significant rise of IL-10 concentration in cases of severe hepatic lesions.…”

Section: Discussionsupporting

confidence: 91%

“…A study on Egyptian patients' demonstrated higher serum IL10 and TNF-α levels compared to non-infected control [15,16,22]. B cell activating factor (BAFF) is essential in B lymphocytes development, maturation and activation [23].…”

Section: Introductionmentioning

confidence: 99%

Seeking markers to distinguish HCV-Infected-autoimmune subjects from uninfected-autoimmune patients

Maghraby¹,

Kamel²,

Fayed³

et al. 2019

Russ Open Med J

View full text Add to dashboard Cite

Introduction -Egypt has the highest prevalence of hepatitis C virus (HCV) infection which is reported to be associated with autoimmune manifestations. Aim -There is a need for markers that enable differentiation between viral and non-infected-autoimmune patients. Material and Methods -Levels of the B-cell activation factor (BAFF), IL6, IL10 and TNF-α were quantified by ELISA in sera from HCVinfected-autoimmune patients (HCV-AI), HCV-infected patients with no autoimmune diseases (HCV-NAI), non-infected autoimmune patients (NIAI) and healthy control humans (C). Results -HCV-infected patients were 12.96, 8.33, 69.44 and 36.11% positive for the auto-antibodies ANA, AMA, ASMA and AGPCA respectively. The BAFF level was significantly (P<0.05) higher among the NI-AI patients compared to the HCV-NAI, HCV-AI patients and healthy control humans (C). For the IL6, no significant differences were seen between various patients' groups. In case of the IL10, its , levels were significantly higher (P<0.05) in the HCV-AI, NI-AI and HCV-NAI patients in comparison to the C humans. Levels of TNF-α were significantly (P<0.001 and 0.0001) higher amongst the HCV-NAI and HCV-AI than in the NI-AI patients respectively. Also, levels of the TNF-α were significantly (P<0.0001) higher amongst the C compared to the NI-AI. Levels of TNF-α were not significant amongst the HCV-NAI and HCV-AI patients than in C subjects. Conclusion -The obtained results showed that both IL6 and BAFF can serve as markers for autoimmunity and/or autoimmunity resulting from severe HCV infection, whereas, IL10 and TNF-α can be considered as markers for HCV infection in Egypt (genotype is mostly 4a).

show abstract

“…Interleukin (IL)‐10, an immunomodulatory cytokine mainly secreted by regulatory T cells, monocytes and macrophages, has important roles in inducing immune tolerance by inhibiting antigen‐specific T‐cell proliferation, downregulating costimulatory molecule and MHC II expression on antigen‐presenting cells, inhibiting DC maturation, and inhibiting the production of proinflammation factors, such as tumour necrosis factor (TNF)‐α, interferon‐γ, IL‐6 and IL‐12 . Some studies reported that IL‐10‐producing DCs mediate tolerogenic effects by inhibiting T‐cell activation and enhancing the differentiation of regulatory T cells, which suggests IL‐10 is a potential therapeutic factor for inducing immunological tolerance after LT. Fas ligand (FasL) expressed on antigen‐presenting cells is a type II transmembrane protein belonging to the tumor necrosis factor superfamily, which combines with Fas expressed on T cells to initiate the apoptosis of specific activated T cells, resulting in the downmodulation of immune responses and maintenance of T‐cell tolerance .…”

Section: Introductionmentioning

confidence: 99%

Effects of IL‐10‐ and FasL‐overexpressing dendritic cells on liver transplantation tolerance in a heterotopic liver transplantation rat model

Zhang

Zhu

et al. 2019

Immunol Cell Biol

View full text Add to dashboard Cite

Acute rejection is the major determinant for the long-term survival of donor liver after liver transplantation (LT). The aim of this study was to examine the therapeutic potential of interleukin (IL)-10-FasL-overexpressing immature dendritic cells (imDCs) to induce local immunosuppression in liver grafts. imDCs derived from donors were transduced by lentiviral vectors expressing human IL-10 and/or Fas ligand (FasL) gene(s), and the expression of surface molecules and the ability to induce T-cell proliferation were measured. imDCs were intraperitoneally injected into recipient rats as a model of LT to examine the rejection grade [Banff rejection activity index (RAI)], liver functions [Alanine aminotransferase, Aspartate aminotransferase (AST) and total bilirubin (TBIL)] and post-transplant survival. IL-10 and FasL co-transduction of imDCs induced a greater reduction in CD80, CD86 and major histocompatibility complex class II (MHC II) expression, as well as T-cell proliferation, but increased levels of IL-10 and FasL in culture supernatants compared with mono-transduced or untransduced imDCs (P < 0.05). The infusion of co-transduced imDCs in LT recipients reduced RAI scores, decreased plasma AST and TBIL, and prolonged survival compared with mono-transduced or untransduced imDC-treated liver allografts. These findings demonstrated that the transfusion of IL-10-FasL/imDCs enhanced immune tolerance and prolonged the survival of liver allografts after LT. The immunomodulatory activity of IL-10-and FasL-modified imDCs might be a new therapeutic approach to prevent organ rejection in clinical transplantation.

show abstract

Serum Cytokine of IL-10 and IL-12 in Chronic Liver Disease: The Immune and Inflammatory Response

Cited by 42 publications

References 31 publications

The balance of type 1 and type 2 immune responses in the contexts of hepatitis B infection and hepatitis D infection

The balance of type 1 and type 2 immune responses in the contexts of hepatitis B infection and hepatitis D infection

Seeking markers to distinguish HCV-Infected-autoimmune subjects from uninfected-autoimmune patients

Effects of IL‐10‐ and FasL‐overexpressing dendritic cells on liver transplantation tolerance in a heterotopic liver transplantation rat model

Contact Info

Product

Resources

About